Abstract
Introduction
Cancer is a leading cause of mortality worldwide, accounting for 13% of deaths (7.4 million) [3] . [4] . This intertwined network of metalloproteases and inhibitors, along with proteolytic enzymes from other catalytic classes, has been termed the 'protease web'. It is responsible for maintenance of tissue homeostasis and its perturbation is undoubtedly linked with pathologies such as cancer, though the interconnectedness of the web can make it difficult to define unique functions for particular proteases [5] .
Some TIMPs, in particular TIMP-3, can also inhibit MMP-related proteases of a disintegrin and metalloproteinase (ADAM) and a disintegrin and metalloproteinase with thrombospondin-like motifs (ADAMTS) families that also have important roles in cell signalling and ECM organization

Originally it was believed that MMPs were key players in tumour development and progression due to their ability to clear a path for cancer cells to invade matrix barriers and migrate through tissue stroma. This notion of MMPs as pro-tumorigenic and pro-metastatic enzymes that was prevalent in the 1980s to 1990s spawned the development of synthetic matrix metalloproteinase inhibitors (MPIs) as cancer therapeutics. Animal studies were encouraging, showing that broad-spectrum MPIs were in many instances effective in preventing metastasis and inhibiting invasion and angiogenesis. However, in the clinic, these agents proved largely disappointing. Several phase III clinical trials with broad-spectrum inhibitors failed due to lack of efficacy and severe musculoskeletal side effects. Moreover, small-cell lung cancer and pancreatic cancer patients treated with the more specific MPI
Tanomastat showed a poorer survival than placebo-treated patients [6, 7] . There were however some positive indications: for instance, in a randomized trial of non-resectable gastric cancer patients a modest but not significant survival benefit was shown for treatment with the broad-spectrum inhibitor marimastat. Of interest, analysis of a subgroup of patients excluding individuals with more advanced or rapidly progressing disease revealed an impressive significant 2 year survival benefit of 13% [8] .
So the key question is-why did the broad-spectrum MPIs fail? The consensus that has emerged over the past decade from analysis of the clinical trial data and from use of more sophisticated transgenic mouse models of cancer is that MPIs in general are less effective in advanced disease [7, 9] [11, 12] . These latter findings emphasize the complex nature of MMPs and may further explain why broad-spectrum MMP inhibition failed as a therapeutic approach and may sometimes result in an unfavourable outcome [13] . Furthermore [17, 18] . MMP-3 has a large repertoire of ECM and nonmatrix substrates [19] . Hence [35, 36] [65, 66] . [65, 67] . Furthermore, in separate investigations, increased MMP12 expression in tumour specimens was associated with a lower rate of lymph node metastasis and a better 2 year survival in gastric cancer [68] , with the absence of hepatic metastases [69] and less extensive invasion into the intestinal wall, lymphatics and blood vessels, which was linked with a better overall survival in colorectal cancer [70] . The expression of both human and mouse proteases have been investigated in an orthotopic model of lung cancer using the human/mouse Affymetrix protease microarray [71] . Host [74] , had a significantly prolonged overall survival compared to patients with the common allele [75] . Based 64, 66, 67, 71] , reducing VEGF expression [65, 66] and preventing uPAR-mediated endothelial cell migration [73] , further highlighting its complex activity. Identification of the relevant bioactive molecules for each cellular source appears to be the key to understanding the function of MMP-12 in cancer.
MMP-3
MMP-3 is a member of the stromelysin subfamily of MMPs, which comprises stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11
. Two human cancer cell lines derived from the same parental cell line MDA-MB-435 showed a different metastatic potential in athymic mice (M-4A4, NM-2C5). Expression analysis further showed a 20-fold increase in MMP-8 expression in the non-metastatic cell line NM-2C5 compared to the metastatic cell line M-4A4. Overexpression of MMP8 in M-4A4 cells and ribozyme knockdown in NM-2C5 cells reversed the metastatic phenotypes of both cell lines. Interestingly, orthotopic injection of mice with the non-metastatic cells treated with ribozymes resulted in a higher number of lymph node metastases than lung metastases. In collaboration with other research groups, we further explored the anti-metastatic potential of MMP
Subcutaneously injected MMP-12 overexpressing CT26 murine colon cancer cells formed smaller tumours with a longer latency, a lower microvessel density, reduced VEGF expression and increased angiostatin expression compared to control CT26 murine colon cancer cells. Mice bearing MMP-12-expressing cancer cells developed less metastases and had a longer overall survival. Consistent with these findings, liposomal delivery of Mmp12 to tumours induced by subcutaneous injection of CT26 colon cancer cells inhibited tumour growth and vascularization
Additionally, it has been suggested that MMP-12 may exert its anti-angiogenic function through urokinase plasminogen activator receptor (uPAR) cleavage rather than angiostatin production using MMP-12 overexpressing MCF-7 and MDA-MB-231 breast cancer cells and nu/nu (CD-1) BR mice [73]. MMP12 overexpression inhibited microvascular endothelial cell (MVEC) invasion through Matrigel and formation of capillary-like tubes. Interestingly, the antiangiogenic activity of MMP-12 was not related to the generation of angiostatin as addition of exogenous plasminogen did not alter angiostatin production of MMP-12 overexpressing cells. On the other hand, immunohistochemical staining indicated that MMP-12 was involved in uPAR cleavage on MVECs, disrupting its ability to interact with integrins and eliminating uPAR-driven pericellular proteolysis that enables endothelial cells to move within tissues. In vivo, a reduced vascularization of Matrigel sponges was observed in C57/BL6 mice after subcutaneous injection of Matrigel suspension containing conditioned media from the overexpressing cells. Furthermore, orthotopic injection of MMP-12 overexpressing cells in nu/nu (CD-1) BR mice resulted in a reduced tumour volume. An SNP analysis of eight SNPs in six genes (MMP1, MMP2, MMP3, MMP7, MMP9, MMP12) revealed that small cell lung cancer patients carrying the G allele of the -82A/G MMP12 polymorphism, which is associated with a higher gene expression in reporter gene assays
MMP-19
Together with [83] [84] [85] [86] [87] . Mmp19-knockout and wild-type mice have been subjected to the transplantation chamber assay using malignant murine PDVA keratinocytes cultured on a collagen gel to examine the effects of MMP-19 on tumour invasion and angiogenesis [88] . Transplants from Mmp19-knockout mice showed a progressive infiltration of host-derived cells, increased endothelial cell migration and tumour invasion. [89] . [91] [92] [93] [94] . Similarly, MMP-26 expression was reduced in the surroundings of the most dedifferentiated and invasive cancer islands of colon cancer [83] . MMP-26 down-regulation was also found in endometrial carcinoma compared to endometrial hyperplasia lesions or normal endometrial tissue [95, 96] . On the RNA level, however, we found a positive correlation between MMP26 expression and Gleason score in prostate cancer patients whereas no expression was found in head and neck squamous cell carcinoma [97, 98] 
Analysis of basic fibroblast growth factor (bFGF)-treated Matrigel implants confirmed an increase in vascularization in Mmp19-null mice. MMP-19 expression was found in host mesenchymal cells but not in capillary endothelial cells or inflammatory cells. In vitro it was shown that capillary-like formation of human MVECs was inhibited after addition of recombinant MMP-19 to the Matrigel. Peptide mass fingerprinting of the Matrigel matrix revealed nidogen-1 to be cleaved in the presence of MMP-19, disrupting its ability to crosslink collagen IV and laminin and stabilize microvessels
From these data, it appears that MMP-19 is involved in vascularization of tumours. However how MMP-19 acts and whether its role is attributed to a single function or multiple distinct activities most likely needs to be clarified in relation to its cellular source being endothelial, mesenchymal or inflammatory.
MMP-26
